Who is sponsoring HEDNet2?

HEDNet2 is sponsored by Montefiore Medical Center.

What condition does HEDNet2 study?

HEDNet2 studies Migraine, Tension-type Headache, Primary Headache Disorder.

What drugs are being tested in HEDNet2?

Interventions: Sumatriptan 100 mg, Naproxen.

What is the status of HEDNet2?

HEDNet2 is currently COMPLETED.

Last reviewed 2018-05-01 · How we verify

A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED) (HEDNet2)

NCT00449787 Phase 4 COMPLETED Results posted

2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment. The goal of this study is to compare two medications, naproxen and sumatriptan, to determine which is better for the treatment of recurrent headache within 24 hours of emergency department discharge.

Details

Lead sponsor	Montefiore Medical Center
Phase	Phase 4
Status	COMPLETED
Enrolment	401
Start date	2007-03
Completion	2009-07

Conditions

Migraine
Tension-type Headache
Primary Headache Disorder

Interventions

Sumatriptan 100 mg
Naproxen

Primary outcomes

Numerical Rating Scale — Baseline, two hours
Within 48 hours of ED discharge, participants were allowed to take the investigational medication. At the moment they took the investigational medication, they were asked to record a number from 0 to 10, which represented their headache. 0 signified no pain and 10 signified the worse pain imaginable. Two hours later, participants were asked again to record their pain on a scale from 0 to 10. The outcome is the change in pain between baseline and two hours and will be a number between 0 and 10. Greater numbes signify greater relief

Countries

United States